Quantum BioPharma Ltd. cash flow to debt ratio of -447.52% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Quantum BioPharma Ltd.'s free cash flow has decreased 21.88% from $-6.88M last year to $-8.38M, signaling decreasing performance

Quantum BioPharma Ltd.'s debt to equity ratio is 1.46, which means that the company's assets are unhealthy financed, signaling financial risk.

Quantum BioPharma Ltd.'s debt has increased relative to shareholder equity from 0.07 last year to 1.46 today, signaling weakened financials

Quantum BioPharma Ltd. has a net cash position, so leverage is healthy.

Quantum BioPharma Ltd.'s interest coverage ratio is -11.73, which means that the company struggles to meet interest obligations, signaling financial risk.

Quantum BioPharma Ltd. has insufficient data to evaluate this check.

Quantum BioPharma Ltd.'s short-term assets of $6.47M exceed its short-term liabilities of $6.05M

Quantum BioPharma Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Quantum BioPharma Ltd.'s return on equity of -621.76%, is lower than 15.00%, indicating bad performance

Quantum BioPharma Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Quantum BioPharma Ltd. had positive net income in only 0 out of 5 years, indicating unstable earnings

Quantum BioPharma Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it

Quantum BioPharma Ltd. has negative free cash flow, indicating cash burn

Quantum BioPharma Ltd.'s yearly earnings has decreased 84.30% since last year from $-14.20M to $-26.18M, signaling decreasing performance

Quantum BioPharma Ltd.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC 819.14% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Quantum BioPharma Ltd. has insufficient revenue history to calculate 3-year revenue CAGR.

Quantum BioPharma Ltd. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Quantum BioPharma Ltd. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Quantum BioPharma Ltd. has insufficient data to evaluate this check.

Quantum BioPharma Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Quantum BioPharma Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Quantum BioPharma Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Quantum BioPharma Ltd. has insufficient data to evaluate this check.

Quantum BioPharma Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Quantum BioPharma Ltd. has negative shareholder equity; price-to-book is not meaningful and the check fails

Quantum BioPharma Ltd. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue